Increased China R&D Spending will Create More Competition for the Western Medical World
Ten years ago, China’s domestic firms were producing second class drug eluting stents and primarily generic drugs. However, as a result of a huge increase in Chinese venture capital, strong government support, and other financial resources, Chinese R&D in the medical space... Read More